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was heated under microwave irradiation (120 o C) for 90 mins. The reaction was quenched with H 2 O, extracted with EtOAc and then the organic extracts were dried and concentrated. Purification by reverse phase liquid column chromatography (25-75% acetonitrile: water with 0.1% trifluoroacetic acid)
provided 5-(3-chlorophenyl)-3-(pyridine-2-yl)-1,2,4-oxadiazole, 9. 
2-(5-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl)pyridine (10):
To neat 2-cyanopyridine (1 eq) at rt was added hydrazine monohydrate (1.1 eq), followed by ethanol (20 M). After 12h at rt, the solvent was removed and cold hexanes (1.0 M) were added to the reaction residue. The heterogeneous mixture was filtered. After the solid was washed with cold hexanes (1.0 M), the white solid was dried to afford picolinimidohydrazide (86%).
To a mixture of picolinimidohydrazide (1.0 eq) and Na 2 CO 3 (1.0 eq) was added dimethylacetamide and THF (3:1, 1.0 M). The resulting yellow suspension was cooled to 0 °C. In a separated vial was added 3-chlorobenzoyl chloride (1.0 eq) and dimethylacetamide (1.0 M). This solution was added dropwise to the reaction mixture over 5 min. The bright yellow reaction mixture was allowed to stir overnight at rt.
The heterogenous mixture was filtered, washed with water (2x), EtOH (2x) and allowed to air dry. The resulting white solid was suspended in ethylene glycol and heated to 190 °C for 30 min. After the heat was removed and the reaction reached rt, the reaction was extracted with EtOAc:water (1:1). The organic layer was collected and washed with water, brine, dried (MgSO 4 ) and filtered. Concentration and purification by reverse phase liquid column chromatography (25-75% acetonitrile: water with 0.1% trifluoroacetic acid) provided 2-(5-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl)pyridine, 10. 3-amino-N-(3-chloro-4-fluorophenyl)picolinamide (12): 3-((Tert-butoxycarbonyl)amino)picolinic acid (71 mg; 0.30 mmol) was dissolved in DMF (1.5 mL) and then treated with HATU (133 mg; 0.350 mmol) followed by DIEA (38 µL; 0.22 mmol). The mixture was stirred for 5 mins, and then 3-chloro-4-fluoroaniline (46 mg; 0.32 mmol) was added and the mixture was stirred at rt for an additional 2 h. The solution was poured into ice and then filtered and dissolved in CH 2 Cl 2 and then concentrated. The residue was redissolved in CH 2 Cl 2 (5 mL) and then treated with TFA (5 mL). After 2 h, the reaction was concentrated and the residue was purified by reverse phase liquid column chromatography (35-75% acetonitrile: water with 0.1% trifluoroacetic acid) provided (32 mg) of 3-amino-N-(3-chloro-4-fluorophenyl)picolinamide, 12.
LCMS
LCMS (Method C): R T = 1.07 min, 98% at 254 nm, m/z = 267 [M + H] + .
2-(4-chloro-3-methoxyphenyl)isoindolin-1-one (13): A mixture of 3-methoxy-4-chloroaniline (1 eq) and phthalic anhydride (1.1 eq) in acetic acid (0.1 M) was heated to reflux. After 3h, water was added and the precipitate was filtered, washed with water (2x) and dried under vacuo.
To a solution of the above compound (1 eq) in acetic acid (0.02 M) was added Zn dust and the mixture was heated to reflux. After 12 h, the reaction was filtered and concentrated. Purification by reverse phase liquid column chromatography (50-75% acetonitrile: water with 0.1% trifluoroacetic acid) provided 2-(4-chloro-3-methoxyphenyl)isoindolin-1-one, 13. (1 eq), 2-pyridine carboxaldehyde (1 eq) and EtOH:water (9:1; 0.1 M) was added NaHSO 3 (2.5 eq) The red mixture was heated to 120 °C in the microwave for 15 min. The reaction was added to EtOAc:water 
LCMS (method
N-(3-chlorophenyl)-3-fluoro-N'-hydroxypicolinimidamide (32).
A solution of 31 (1.0 eq) in 1,4-dioxane (0.5 M) was added via cannula to a solution of 3-chloroaniline (6.0 eq) in 1,4-dioxane (1.0 M).
After 12 h at rt, the reaction was added to EtOAc: H 2 O (1:1). The organic layer was separated and washed with Brine, dried (MgSO 4 ), filtered and concentrated. The crude residue, 32, was taken through to the next step. 
LCMS (method
N-(3-chlorophenyl)-1H-indazol-3-amine (25).
The crude residue was dissolved in DMF (0.63 M) and DBU (3.0 eq) was added. The solution was evenly transferred into microwave vials. In the microwave, the solution was subjected to 175 °C for 60 min. LCMS confirmed product formation, so reaction was added to EtOAc:water (1:1, 0.01M). The organic layer was separated and washed with water (3x), brine and dried (MgSO 4 ). The mixture was filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (10-40% EtOAc: hexanes), followed by recrystallization with EtOH:hexanes to yield, 25, as an off-white powder (68% over 2 steps). 
N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (26):
3-bromo-1H-pyrazolo[4,3-b]pyridine (28).
A mixture of 3-fluoro-2-formylpyridine, 27, (1.0 eq) and anhydrous hydrazine (8.0 eq) was heated to 110 °C. After 16h, the reaction was cooled to rt and slowly poured onto ice water. After extracting with EtOAc (3 x), the collected organic layers were washed with Brine (100 mL), dried (MgSO 4 ), filtered and concentrated to provide a dark brown oil.
LCMS (method A): single peak (214 and 254 nm), R T = 0.102 min, MS (ESI
The crude residue was dissolved in 2 M NaOH (0.5 M) and a solution of Br 2 (1.0 eq) in 2 M NaOH (1.0 M) was added dropwise. After 3 h at rt, NaHSO 3 (aqueous) (1 mL) was added followed by 4 N HCl (~1.0M). A solid precipitated formed and was collected by filtration and air dried affording 28 as an off-white solid (29% yield over 2 steps). 
LCMS (method
tert-Butyl 3-bromo-1H-pyrazolo[4,3-b]pyridine-1-carboxylate (29).
To a solution of 28 (1.0 eq), DMAP (10 mg) and Et 3 N (1.15 eq) in dry DMF (0.25 M) was added Boc 2 O (1.1 eq) at rt. After 16 h at rt, the reaction was added to EtOAc: H 2 O (1:1). The separated organic layer was washed with water (2x), brine, dried (MgSO 4 ), filtered and concentrated to provide desired product 29 (88% yield).
Material was taken through without further purification. 
LCMS (method
In vitro Pharmacology:
The in vitro pharmacology methods and mGlu selectivity have already been published. 
In-Vitro DMPK Methods
Intrinsic clearance in human and rat liver microsomes
Human or rat liver microsomes (0.5 mg/mL) and 1 µM test compound were incubated in 100 mM potassium phosphate pH 7.4 buffer with 3 mM MgCl 2 at 37 ºC with constant shaking. After a 5 min preincubation, the reaction was initiated by addition of NADPH (1 mM where Q h (hepatic blood flow) is 70 mL/min/kg for rat and 21 mL/min/kg for human.
Plasma Protein Binding
The protein binding of each compound was determined in the plasma of multiple species via equilibrium dialysis employing HTDialysis Teflon dialysis chamber and cellulose membranes (MWCO 12-14 K) (HTDialysis LLC, Gales Ferry, CT). Plasma was added to the 96 well plate containing test compound and mixed thoroughly for a final concentration of 5 µM. Subsequently, 150 µL of the plasma-compound mixture was transferred to the dialysis chamber, with an accompanying 150 µL of phosphate buffer (25 mM, pH 7.4) on the other side of the membrane. The device plate was sealed and incubated for 4 hours at 37 ºC with shaking. At completion, aliquots from each chamber were diluted 1:1 with either plasma (for the buffer sample) or buffer (for the plasma sample) and transferred to a new 96 well plate, at which time ice-cold acetonitrile containing internal standard (50 ng/mL carbamazepine) (2 volumes) was added to extract the matrices. The plate was centrifuged (3000 rcf, 10 min) and supernatants transferred and diluted 1:1 (supernatant: water) into a new 96 well plate, which was then sealed in preparation for LC/MS/MS analysis. Each compound was assayed in triplicate within the same 96-well plate. Fraction unbound was determined using the following equation:
LC/MS/MS Bioanalysis of Samples from In Vitro Assays
Samples were analyzed on a Thermo Electron TSQ Quantum Ultra triple quad mass spectrometer (San Jose, CA) with electrospray ionization (ESI), Shimadzu LC-10ADvp pumps (Columbia, MD) , and a Leap Technologies CTC PAL autosampler (Carrboro, NC). Analytes were separated by gradient elution using Fortis C18 (3.0 x 50 mm, 3 µm) columns (Fortis Technologies Ltd, Cheshire, UK) thermostated at 40°C. HPLC mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile. The gradient started at 30% B after a 0.2 min hold and was linearly increased to 95% B over 0.8 min; hold at 95% B for 0.2 min; returned to 30% B in 0.1 min. The total run time was 1.3 min and the HPLC flow rate was 0.5 mL/min. Compound optimization, data collection and processing was performed using Thermo Electron's QuickQuan software (v2.3) and Xcalibur (v2.0.7 SP1).
Cytochrome P450 Cocktail Inhibition Assay in Human Liver Microsomes
µM; 2D6: Dextromethorphan, 5 µM; 3A4: Midazolam, 2 µM) were mixed for cocktail analysis. The positive control for pan-P450 inhibition (miconazole) was included alongside test compound in analysis.
A reaction mixture of 100 mM Kpi, pH 7.4, 0.1 mg/mL human liver microsomes (HLM) and Substrate
Mix is prepared and aliquoted into a 96-deepwell block. Test compound and positive control (in duplicate) were then added such that the final concentration of test compound ranged from 0.1 -30 µM.
The plate was vortexed briefly and then pre-incubated at 37 ºC while shaking for 15 minutes. The reaction was initiated with the addition of NADPH (1 mM thermostated at 40 ºC. HPLC mobile phase A was 0.1% formic acid in water (pH unadjusted), mobile phase B was 0.1% formic acid in acetonitrile (pH unadjusted). The gradient started at 10% B after a 0.2 min hold and was linearly increased to 90% B over 1.2 min; held at 90% B for 0.1 min and returned to 10% B in 0.1 min followed by a re-equilibration (0.9 min). The total run time was 2.5 min and the HPLC flow rate was 0.5 mL/min. The source temperature was set at 500 ºC and mass spectral analyses were performed using multiple reaction monitoring (MRM), with transitions specific for each compound utilizing a Turbo-Ionspray® source in positive ionization mode (5.0 kV spray voltage).
The IC 50 values for each compound were obtained for the individual CYP enzymes by quantitating the inhibition of metabolite formation for each probe substrate. A 0 µM compound condition (or control) was set to 100% enzymatic activity and the effect of increasing test compound concentrations on enzymatic activity could then be calculated from the % of control activity. Curves were fitted using XLfit 5.2.2 (four-parameter logistic model, equation 201) to determine the concentration that produces half-maximal inhibition (IC 50 ).
In vitro Biotransformation
VU0418506 (26) 
CYP Induction in Human Hepatocytes (4 Day Protocol)
Pooled human hepatocytes (BMS inventory) were thawed in a water bath and resuspended in TRL Recovery media. Cells were then centrifuged at 700 rpm for 10 min and the media decanted. The remaining cell pellet was resuspended to 850k cells/mL in TRL Plating media and plated in 384-well format (17k cells per well) and the incubated at 37° C for 3 hours. An initial media change was carried out with Geltrex (GTX) and the cells incubated overnight at 37° C. On day 2, test compound (VU0418506) was dissolved in DMSO to yield a 20 mM stock. Positive controls (listed below) and test compound were then plated into 96-well Assay Master Plate according to a predetermined plate map and serially diluted to afford a concentration range. Following aspiration of the old media on the plated cells, controls and test compounds were diluted in TRL plating media and dosed to the cells using a fully automated BRAVO liquid handling system and then incubated overnight at 37° C. Media was removed on day 3 as above and the controls and test compound re-dosed over the same concentration range. On day 4, the media was removed and the cells washed with Krebs-Henseleit Buffer (KHB) and then lysed for RNA purification and RT-PCR (Roche Lightcycler, AgPath 1 step PCR kit (Invitrogen -4387391) ).
The following controls are included in every plate: 
Time Course PK Studies
IV cassette PK experiments in rats were carried out according to methods described previously (Bridges et al. Pharmacol. Res. Perspect. 2014; reference 49) . Briefly, A cassette of compounds (n = 4-5/cassette) were formulated from 10 mM solutions of compounds in DMSO. In order to reduce the absolute volume of DMSO that was administered, the compounds were combined and diluted with ethanol and PEG 400 to achieve a final concentration of 0.4-0.5 mg/mL for each compound (2 mg/mL total) administered in each cassette. The final dosing solutions consisted of approximately 10% ethanol, 40% PEG400, and 50% DMSO (v/v). Each cassette dose was administered IV via the jugular vein to thermostated at 40 ºC. HPLC mobile phase A was 0.1% formic acid in water (pH unadjusted), mobile phase B was 0.1% formic acid in acetonitrile (pH unadjusted). The source temperature was set at 500 ºC and mass spectral analyses were performed using multiple reaction monitoring (MRM), with transitions specific for each compound utilizing a Turbo-Ionspray® source in positive ionization mode (5.0 kV spray voltage). The calibration curves were constructed, and linear response was obtained by spiking known amounts of test compound in blank brain homogenate or plasma. All data were analyzed using AB Sciex Analyst software v1.5.1. The final PK parameters were calculated by noncompartmental analysis using Phoenix (version 6.2) (Pharsight Inc., Mountain View, CA). 
